Sonoma Pharmaceuticals (SNOA) Return on Sales (2010 - 2026)

Sonoma Pharmaceuticals' Return on Sales history runs 17 years deep, the most recent figure standing at 0.0% for Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a 0.0% change from a year earlier, with the FY2026 full-year figure at 0.0%, changed 0.0% from the prior year.
• Return on Sales grew to 0.0% in Q1 2026 per SNOA's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q3 2025 and bottomed at 0.01% in Q4 2022.
• The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.0%.
• Biggest YoY gain for Return on Sales was 0 bps in 2022; the steepest drop was 1 bps in 2022.
• Year by year, Return on Sales stood at 0.01% in 2022, then surged by 58 bps to 0.0% in 2023, then increased by 6 bps to 0.0% in 2024, then rose by 28 bps to 0.0% in 2025, then soared by 45 bps to 0.0% in 2026.
• Per Business Quant, the three latest SNOA Return on Sales figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).